BioSpace News Archive

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, is pleased to announce that it has raised NOK500m via an over subscribed Private Placement that took place via an accelerated book building process after close of market on 4 May 2020.

Evogene Ltd., a leading biotechnology company aiming to revolutionize the development of novel products for life-science based industries, by utilizing cutting edge computational biology technologies, announces a letter to the shareholders from President and CEO, Ofer Haviv.

Century Therapeutics, developer of induced pluripotent stem cell -derived allogeneic cell therapies for cancer, announced the formation of its Scientific Advisory Board to include several renowned experts in the fields of developmental and stem cell biology, genetics, and immuno-oncology.

Monotherapy Phase I dose escalation remains ongoing; BT5528 appears well-tolerated as dosing approaches clinically relevant levels

Acceleron Pharma Inc. announced it will host a webcast and conference call on Monday, May 11, 2020 at 5:00 p.m. EDT to discuss its first quarter 2020 operating and financial results.

Total product and royalty revenues of $569 million (+24% vs Q1 2019) for the quarter ended March 31, 2020; Jakafi® (ruxolitinib) revenues of $459 million in Q1 2020 (+22% vs Q1 2019)

Updated data will be presented on first patient dosed in Phase 1/2 clinical trial for cystinosis and first patient treated using plato™ gene therapy platform in Phase 2 Fabry disease clinical trial

Expands and diversifies Alexion’s hematology, neurology and critical care commercial portfolio with transformative Factor Xa inhibitor reversal agent

Omeros Corporation, announced that the company will issue its first quarter financial results for the period ended March 31, 2020, on Monday, May 11, 2020, after the market closes.

Castle Biosciences, Inc. announced the publication of a clinical utility model for its cutaneous squamous cell carcinoma prognostic test, DecisionDx®-SCC, for patients diagnosed with high-risk cutaneous SCC.